Pilot Study to Evaluate the Role of EBUS in the Diagnosis of Acute PE in Critically Ill Patients

Acute Pulmonary Embolism Clinical Trial

— VEBUS  

Official title:

Pilot Study to Evaluate the Role of Endobronchial Ultrasound (EBUS) in the Diagnosis of Acute Pulmonary Embolism in Critically Ill Patients

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04047784
• Other study ID #: IRB# 19-000295
• Status: Enrolling by invitation
• Phase: N/A
• Start date: August 12, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2023
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Acute pulmonary embolism (PE) in critically ill patients is common and often life threatening. The diagnosis of acute PE is often entertained in intensive care unit patients who develop unexplained hypotension or hypoxemia. Obtaining diagnostic confirmation of acute PE with a contrast-enhanced computed tomography of the chest (CT angiogram) may be difficult as patients are often too unstable for transport to the CT scanner or have renal insufficiency limiting the ability to receive intravenous contrast agents. Making or excluding the diagnosis of acute PE in these patients is critically important, as hemodynamic instability or right heart dysfunction, if due to PE, puts patients in the massive or submassive category and increased mortality risk. More aggressive therapies such as thrombolysis, extracorporeal membrane oxygenation or surgical embolectomy are often entertained. The investigators have previously described a case where endobronchial ultrasound (EBUS) was employed in the diagnostic algorithm of suspected acute PE and significantly affected treatment recommendations. The investigators believe that, in these patients, use of EBUS to assess for thrombotic occlusion of the central pulmonary vasculature can fill a critical gap in the decision tree for management of these patients.

EBUS has become part of the diagnostic approach in a number of clinical situations, including the workup and staging of suspected malignancy, unexplained lymphadenopathy, and diagnosis of mediastinal and parabronchial masses. There is strong evidence that EBUS is equivalent to mediastinoscopy in the mediastinal staging of lung cancer. The number of physicians skilled and experienced in performance of EBUS has increased dramatically, and training in the procedure is frequently obtained in a pulmonary fellowship.

To our knowledge, there have been no prospective studies that investigate the use of EBUS as a tool for the diagnosis of acute central pulmonary embolism in critically ill patients where obtaining diagnostic confirmation of this diagnosis with a contrast-enhanced computed tomography of the chest is not safe or feasible.

Description:

This is a single center, pilot study to evaluate critically ill patients diagnosed with acute pulmonary embolism using endobronchial ultrasound (EBUS). The investigators anticipate to enroll 20 subjects at Ronald Reagan UCLA Medical Center and UCLA Medical Center, Santa Monica. The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS.

After informed consent is obtained, the following procedure will be performed:

An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow.

Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion as follow:

Advance the bronchoscopy into the right main bronchus distally to the level of the right lower lobe, between 12 and 3 o'clock position where the interlobar artery of the PA is seen. Then the scope will be pulled back slowly, turning counterclockwise, following the course of the PA on the medial wall of the right bronchial tree until the level of the carina, where the right main PA and the PA trunk are seen. The scope is then turned to the right again, towards 3 o'clock following the right upper lobe bronchus to examine the upper lobar artery. The scope is then advanced into the left main bronchus, towards 9 o'clock to examine the upper lobar artery, then advanced distally to the left lower lobe bronchus to examine the interlobar artery. At the completion of the imaging the EBUS bronchoscope will be withdrawn.

Ultrasound images and video will be stored to the machine and visualized thrombi will be marked.

For patients who have had a chest CT for suspected PE, the investigators will assess sensitivity and specificity of EBUS to visualize or exclude PE. For patients who are unable to have a CT, the investigators will not be able to determine true efficacy, but will report the number of positive and negative studies and follow these patients for outcome and subsequent definitive diagnosis of venous thromboembolism.

As this is a pilot study looking at the feasibility of EBUS for diagnosing acute pulmonary embolism, study personnel performing the EBUS will not be blinded to the clinical diagnosis and the management of the subject. A brief report of the procedure results will be uploaded in the patient's medical record. Any clinically relevant findings from the EBUS will be communicated to the subject's treating team. Regardless of the findings, a note stating that the EBUS technique is not yet established for evaluating acute pulmonary embolism in critically ill patients will be emphasized in order to prevent any bias in the patient's clinical care.

Pulmonary Vascular Mapping Substudy:

Of the 60 total subjects enrolled in the study, approximately 20 subjects under the criteria below will be enrolled at Ronald Reagan UCLA Medical Center and UCLA Medical Center, Santa Monica undergoing clinical bronchoscopy as a part of their standard of care. The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS.

Retrospective Chart Review:

Of the 60 total subjects enrolled in the study, media including images and videos that are previously recorded for 20 patients who underwent a clinical bronchoscopy with EBUS as a part of their standard of care will also be available to our research team without consent from the patient to help supplement the data we obtain from the 20 subjects that are enrolled in the pulmonary vascular mapping substudy.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 60
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient = 18 years of age.

• The patient or patient's surrogate must understand and sign informed consent form (ICF).

• Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism.

Exclusion Criteria:

• Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.

• Endotracheal tube size less than 8.0 mm.

• Contraindications to lidocaine.

Pulmonary Vascular Mapping Substudy:

Enrollment for the pulmonary vascular mapping substudy will be based on the following inclusion and exclusion criteria:

Inclusion criteria:

• Patient = 18 years of age.

• The patient or patient's surrogate must understand and sign informed consent form (ICF).

• Intubated patients undergoing clinical bronchoscopy, as determined by the treating physician.

Exclusion criteria:

• Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.

• Endotracheal tube size less than 8.0 mm.

• Contraindications to lidocaine.

Retrospective Chart Review:

Of the 60 total subjects enrolled in the study, media including images and videos that are previously recorded for 20 patients who underwent a clinical bronchoscopy with EBUS as a part of their standard of care will also be available to our research team without consent from the patient to help supplement the data we obtain from the 20 subjects that are enrolled in the pulmonary vascular mapping substudy.

Related Conditions & MeSH terms

• Acute Pulmonary Embolism
• Embolism
• Pulmonary Embolism

Intervention

Device:
• Endobronchial ultrasound (EBUS)
An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow. Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion. At the completion of the imaging the EBUS bronchoscope will be withdrawn.

Locations

Country	Name	City	State
United States	Ronald Reagan UCLA Medical Center	Los Angeles	California
United States	UCLA Medical Center, Santa Monica	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

References & Publications (7)

Aumiller J, Herth FJ, Krasnik M, Eberhardt R. Endobronchial ultrasound for detecting central pulmonary emboli: a pilot study. Respiration. 2009;77(3):298-302. doi: 10.1159/000183197. Epub 2008 Dec 9. — View Citation

Ernst A, Anantham D, Eberhardt R, Krasnik M, Herth FJ. Diagnosis of mediastinal adenopathy-real-time endobronchial ultrasound guided needle aspiration versus mediastinoscopy. J Thorac Oncol. 2008 Jun;3(6):577-82. doi: 10.1097/JTO.0b013e3181753b5e. — View Citation

Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest. 1995 Oct;108(4):978-81. doi: 10.1378/chest.108.4.978. — View Citation

Tanner NT, Pastis NJ, Silvestri GA. Training for linear endobronchial ultrasound among US pulmonary/critical care fellowships: a survey of fellowship directors. Chest. 2013 Feb 1;143(2):423-428. doi: 10.1378/chest.12-0212. — View Citation

Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008 Mar 6;358(10):1037-52. doi: 10.1056/NEJMra072753. No abstract available. — View Citation

Torbicki A, Galie N, Covezzoli A, Rossi E, De Rosa M, Goldhaber SZ; ICOPER Study Group. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol. 2003 Jun 18;41(12):2245-51. doi: — View Citation

Yasufuku K, Pierre A, Darling G, de Perrot M, Waddell T, Johnston M, da Cunha Santos G, Geddie W, Boerner S, Le LW, Keshavjee S. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinosco — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CT angiogram results (if obtained)	For patients who have had a chest CT for suspected PE, the investigators will obtain a copy of the participant's chest CT for suspected PE report.	2 years
Primary	Patient treatment	For patients who are unable to have a CT, the investigators will not be able to determine true efficacy, but will report the number of positive and negative studies. Patient treatment will be reported as: Catheter Directed Lysis; Heparin Drip; Surgical Embolectomy; Thrombolysis; No Treatment for Pulmonary Embolism (PE)	2 years
Primary	Patient outcome	For patients who are unable to have a CT, the investigators will not be able to determine true efficacy, but follow these patients for outcome and subsequent definitive diagnosis of venous thromboembolism. Subsequent patient outcome will be reported as: Alive; Extended hospitalization; Intervention to prevent impairment or damage; Life-threatening condition; Disability; Death	2 years
Primary	Assess sensitivity and specificity of EBUS to visualize or exclude PE compared to the chest CT.	Ability for EBUS will be reported by its ability to identify each major branch and reporting what branched not identified as: Main Pulmonary Artery (MPA); Right Pulmonary Artery (RPA); Truncus Anterior (TA) or Ascending Branch; Right Interlobar Artery or Descending Branch; Right Basal Trunk; Left Pulmonary Artery (LPA); Left Interlobar Artery; Left Basal Trunk; Other	2 years
Primary	Report any complications	Complications during or after the procedure will be reported as: Airway Bleeding; Airway Injury; Hypotension as defined by < 65 mmHg or need to escalate vasopressors; Hypoxia as defined by < 90%; Other; None	2 years
Primary	Assess sensitivity and specificity of EBUS to visualize or exclude PE by its ability to identify a clot.	Ability for EBUS will be reported by its ability to identify a clot and reporting the location of the clot as: Main Pulmonary Artery (MPA); Right Pulmonary Artery (RPA); Truncus Anterior (TA) or Ascending Branch; Right Interlobar Artery or Descending Branch; Right Basal Trunk; Left Pulmonary Artery (LPA); Left Interlobar Artery; Left Basal Trunk; Other	2 years
Primary	Assess sensitivity and specificity of EBUS to visualize or exclude PE by its ability to identify flow around clot(s) present.	Ability for EBUS will be reported by its ability to identify flow around clot(s) present and reporting the location of the flow around clot(s) present as: Main Pulmonary Artery (MPA); Right Pulmonary Artery (RPA); Truncus Anterior (TA) or Ascending Branch; Right Interlobar Artery or Descending Branch; Right Basal Trunk; Left Pulmonary Artery (LPA); Left Interlobar Artery; Left Basal Trunk; Other	2 years
Secondary	Other airway finding(s)	Other airway finding(s) will be reported as: Mucus; Blood; Other	2 years

External Links

•   Pulmonary Artery Anatomy